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Abstract
Folate is a source of one-carbons necessary for DNA methylation, a critical epigenetic modification necessary for genomic
structure and function. The use of supplemental folic acid is widespread however; the potential influence on DNA
methylation is unclear. We measured global DNA methylation using DNA extracted from samples from a population-based,
double-blind randomized trial of folic acid supplementation (100, 400, 4000 mg per day) taken for 6 months; including a 3
month post-supplementation sample. We observed no changes in global DNA methylation in response to up to 4,000 mg/
day for 6 months supplementation in DNA extracted from uncoagulated blood (approximates circulating blood). However,
when DNA methylation was determined in coagulated samples from the same individuals at the same time, significant time,
dose, and MTHFR genotype-dependent changes were observed. The baseline level of DNA methylation was the same for
uncoagulated and coagulated samples; marked differences between sample types were observed only after intervention. In
DNA from coagulated blood, DNA methylation decreased (214%; P,0.001) after 1 month of supplementation and 3
months after supplement withdrawal, methylation decreased an additional 23% (P,0.001) with significant variation among
individuals (max+17%; min-94%). Decreases in methylation of $25% (vs. ,25%) after discontinuation of supplementation
were strongly associated with genotype: MTHFR CC vs. TT (adjusted odds ratio [aOR] 12.9, 95%CI 6.4, 26.0). The unexpected
difference in DNA methylation between DNA extracted from coagulated and uncoagulated samples in response to folic acid
supplementation is an important finding for evaluating use of folic acid and investigating the potential effects of folic acid
supplementation on coagulation.
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Introduction
DNA methylation is an epigenetic modification required for
normal gene expression and the chromosomal integrity essential for
embryogenesis [1,2,3]. Folate in the form of N-5-methyltetrahy-
drofolate (5-methylTHF) provides the methyl groups for the
formation of S-adenosylmethionine (SAM), the body’s universal
methyl donor required for DNA methylation. Common single-
nucleotide genetic variants associated with folate metabolism might
have a significant effect on folate-dependent, one-carbon transfer
reactions. One key polymorphism is the 677CRT variant of the
methylenetetrahydrofolate reductase (MTHFR) gene, responsible
for the synthesis of 5-methylTHF. When coupled with low folate
status, the MTHFR 677CRT variant has been reported to be
associated with elevated homocysteine concentrations; reduced
global DNA methylation; and a variation in the risk for many
disorders, including neural tube defects (NTDs) and venous
thrombosis [4,5,6]. Among populations with high prevalences of
the MTHFR T allele and vitamin B12 deficiency, such as the
population in North China in this study [7,8], it has been suggested
that the selective advantage of the T allele in these groups might be
pregnancy-related, such as resistance to anemia and hemorrhage
during childbirth [9]. The MTHFR 677CRT variant may be
associated with a diversion of available methyl groups from the
DNA methylation pathway towards the DNA synthesis pathway
andmoderate the anemia duetoa vitaminB12 deficiency[9,10,11].
Data from small-scale human metabolic studies have provided
evidence that folate depletion and repletion can affect the global
methylation status of DNA from peripheral blood cells [12,13,14].
However, there have been no previous population-based studies
that provide data that describe normal DNA methylation and/or
how it might be affected by initiation of folic acid supplementation
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acid dose, and/or MTHFR genotype.
Based on evidence that periconceptional folic acid significantly
reduces NTD risk [15], folic acid is recommended for NTD
prevention in doses of 400 or 4,000 mg/day for NTD occurrence
and recurrence, respectively, for women of childbearing age [16].
Mandatory folic acid fortification was implemented in the United
States, based on the evidence that folic acid reduces NTD risk and
provides ,100 mg/day [17]. A large-scale, randomized, popula-
tion-based folic acid intervention trial was conducted in Northern
China for the purpose of selecting a specific folic acid dosing
regimen for future NTD prevention programs in which the folate
status responses to 100-, 400-, and 4,000-mg/day folic acid doses
were compared as well as the interaction of folic acid dose with
MTHFR genotype [7,8]. In the present study, samples from the
previous study were utilized to assess whether there were changes
in global DNA methylation in response to folic acid supplemen-
tation among women of reproductive age not exposed to dietary
sources of folic acid or folic acid food fortification. The possibility
of adverse effects of folic acid use through changes in DNA
methylation has been suggested [18]. However, the potential
effects of the initiation and termination of folic acid supplement
use on global DNA methylation is unknown.
This study’s objectives were to determine what, if any, global
DNA methylation changes accompany folic acid supplementation
and withdrawal and if the changes are time-, dose-, or genotype-
dependent.
Materials and Methods
Ethics Statement
All participants provided oral informed consent which was
documented with a signature of the consenting investigator as was
culturally appropriate for the research setting and was permissible
as the study posed no more than minimal risk of harm to the
participant and involved no procedure for which written consent
was normally required outside of a research setting. The study and
consent procedures (including a waiver for the documentation of
informed consent as set forth in 45CFR46.117(c)) were approved
by the Centers for Disease Control and Prevention Institutional
Review Board and the Ethical Committee on Biomedical
Research Involving Human Subjects of the Health Science
Center, Peking University.
Setting and inclusion criteria for participants
Women in the study were recruited from six townships of
Xianghe County, Hebei Province, in Northern China, near
Beijing (the trial is registered at clinicaltrials.gov: NCT00207558).
As previously described, to be eligible for the study, women were
required to live in the township; have a child 2–4 years of age; not
be pregnant or breastfeeding; have no plans to become pregnant
during the subsequent 9 months; be using an intrauterine device
for contraception; have no chronic diseases; have had no folic acid
supplement use within the last 3 months; and have no current
prescription medication use [7]. Participants were screened at
enrollment and excluded if they were either vitamin B12-deficient
(plasma vitamin B12,148 pmol/L) or anemic (hemoglobin
,120 g/L) (Fig. 1). Since folic acid-fortified foods were not
available in China, study participants were not exposed to dietary
sources of folic acid.
Study design
Eligible participants were randomized into three daily folic acid
treatment groups (100 mg, 400 mg, and 4,000 mg) which were
taken for 6 months. Participants had blood samples drawn at
enrollment; after 1, 3, and 6 months of folic acid supplementation;
and 3 months after withdrawal of supplementation. The repeated
measures design of the study allowed each participant to serve as
her own control; therefore, a placebo group was not included. A
double-blind randomization was used to assign equal numbers of
women to each of the folic acid intervention groups as described
previously [7].
Blood collection procedures
Fasting blood samples were collected at the time of enrollment,
and at the end of 1, 3, 6, and 9 months using standard phlebotomy
techniques. For each participant, blood was collected into 7 ml
tubes with EDTA and 3 ml tubes without any anticoagulants
(Vacutainer; Becton Dickinson, Franklin, NJ). After centrifugation,
plasma from the 7 ml tubes and sera from the 3 ml tubes were
removed. Plasma was separated by centrifugation at 4uC, 20006g
for 15 min, and frozen at 220uC within 1 hour of collection. The
serum was separated by the same centrifugation after 1–2 hour of
coagulation at room temperature. All blood cells and clots were
then frozen at 220uC and transported on dry ice to the central
laboratory of the Peking University Health Science Center in
China and stored at 270uC until sent by air courier on dry ice to
the University of Florida in the United States for DNA extraction
and analysis.
Genomic DNA extraction and genotyping
Initially, only blood clots from coagulated blood were shipped
from China and available for genomic DNA analysis. Using a
commercially available blood DNA purification kit (Gentra
Puregene, Qiagen, Valencia, CA), genomic DNA was extracted
from stored frozen blood clots according to the manufacturer’s
instructions. Thawed clots were digested with proteinase K after
dispersal, either by centrifugation through perforated inserts
(Clotspin, Qiagen) or by mincing with paired, curved scalpel
blades in plastic weigh boats. An alternative automated method
(Maxwell 16, blood kit, tissue protocol, Promega, Madison, WI)
produced equivalent DNA yield and results (data not shown).
Samples were hydrated in TE buffer, and DNA concentration was
determined by fluorescent dye binding assay (Quant-iT, Invitro-
gen, Carlsbad, CA) and adjusted to 20 ng/ml.
MTHFR 677 CRT genotyping procedures were described
previously [8]. Samples were genotyped by sequential participant
number and researchers were blinded to dose group and all
participant data. Briefly, MTHFR 677 CRT genotypes were
determined on 3-ml aliquots of genomic DNA by dynamic allele-
specific hybridization [19]. Analyses were performed with dFOLD
and DYNASCORE v. 0.65 software (DynaMetrix Limited,
Stockholm, Sweden; Internet: http://www.dynametrix-ltd.com)
and genotypes were confirmed for 15% of randomly selected
samples with probes for the alternate allele [20].
Sample selection
To assess the effects of folic acid dose, length of exposure,
withdrawal, and MTHFR 677 CRT genotype on global DNA
methylation, a stratified random sample of 135 individuals with 5
blood samples was selected for analysis at each time point (at
enrollment; after 1, 3, and 6 months of supplementation; and 3
months after withdrawal of supplementation; samples n=675)
(Fig. 1). From each daily dose group (100 mg, 400 mg, and
4,000 mg), 45 participants were chosen with the intent to select 15
from within each group to equally represent each of the three
MTHFR genotypes (CC, CT, and TT). As a result of the lower
prevalence of the MTHFR CC genotype, 15 CC samples were not
Folic Acid and Changes in DNA Methylation
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28144Figure 1. Study design and sample selection.
doi:10.1371/journal.pone.0028144.g001
Folic Acid and Changes in DNA Methylation
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28144available from the 4,000 mg/day dose group; therefore, 12 CC
samples were selected, and 3 additional TT samples were added to
attain the n=45 for this subgroup. Sampling was accounted for in
the analysis through weighting and adjusting.
Initially, only blood clots from coagulated blood were available
for genomic DNA analysis. After the global methylation analysis of
the 675 samples from coagulated blood was completed, red blood
cell (RBC) samples from uncoagulated blood from the same
individuals were shipped frozen on dry ice from China to the
United States for additional DNA methylation analysis. These
samples were used for routine DNA methylation confirmatory
testing, at which time it was discovered that there were
inconsistencies between the DNA extracted from coagulated and
uncoagulated blood samples from the same individuals. Therefore,
additional liquid chromatography-mass spectrometry (LC-MS/
MS) analyses using both sample types were preformed. The first
confirmatory testing was a blinded side-by-side extraction and LC-
MS/MS analysis of 1- months and 9 months samples from the
100 mg/day MTHFR CC supplementation group (n=68) (Fig. 1).
Samples for this analysis were selected based on data obtained in
previously analyzed DNA extracted from clots that showed
significant decreases in DNA methylation in this group. The
second was a blinded study designed to completely replicate the
DNA methylation analysis of coagulated samples for the 400 mg/
day (n=30) and 4,000 mg/day (n=29) dose groups using
uncoagulated blood from the same participants for which matched
blood samples were available (total sample n=295) (Fig. 1).
LC-MS/MS analysis of 5-methyl-deoxycytidine (MdCyt)
Prior to digestion, internal standards (biosynthetic [
15N3]dCyt
and [
15N3]MdCyt) were added to 0.5 mg of DNA sample as
described elsewhere [21]. DNA was then digested to deoxynucleo-
sides using the procedure of Quinlivan and Gregory [22]. Digests
were chromatographed [21] on a Luna 3m C18 column
(5063.0 mm; Phenomenex, Torrence, CA) using an ammonium
acetate:methanol gradient. Samples were analyzed in ESI mode
using a triple quadrupole mass spectrometer. Scanning was
performed in selected reaction monitoring (SRM) mode, moni-
toring the mass-to-charge (m/z) transitions of dCyt, 228R112;
[
15N3]dCyt, 231R115; MdCyt, 242R126; and [
15N3]MdCyt,
245R129. Chromatograms were analyzed using the Xcalibur
software package (Thermo; Version 2.0). Concentrations of dCyt
and MdCyt were determined by comparing the analyte/internal
standard (M+0/M+3) peak area ratio to standard curves. The
ratio of MdCyt to total dCyt was used to calculate %MdCyt, i.e.,
%MdCyt=MdCyt/(dCyt+MdCyt)6100. Inter- and intra-assay
variation (relative standard deviation; n=6) was ,2.5%. Addi-
tional details of the methodology have been published elsewhere
[21,22]. The operator (EPQ) was blinded with respect to sample
dose group or genotype. Samples were analyzed in a single
continuous run, ordered only by sequential participant numbers.
To minimize any error due to position in the analysis cue, samples
from the serial blood draws from each participant were assayed in
juxtaposition. Two highly correlated replicate assays were run on
coagulated samples: a complete replication of the enrollment
readings and a two-thirds replication of the 6 and 9 months time
points. Independent analysis of each data set led to the same
interpretation of the results.
Methyl-acceptance assays
To confirm the results of global DNA methylation analysis by
LC-MS/MS, [
3H] methyl-acceptance assays were performed on
representative samples that showed either large or moderate
changes in methylation by LC-MS/MS in DNA extracted from
coagulated blood. Using a modification of the method of Balaghi
and Wagnerm [23], DNA methylation was determined as we have
previously described [13]. The ability of cytosine in DNA to accept
and incorporate [
3H] methyl groups in the presence of SssI
prokaryotic methylase is inversely related to the level of DNA
methylation.
Statistical analysis
Arithmetic means and standard deviations were calculated to
show the participant characteristics and response to folic acid
supplementation and withdrawal. General linear models for
repeated measures were used to determine factor associated with
DNA methylation level and to obtain estimated means and 95%
confidence intervals (CIs) to allow for correlation between the
measurements at sequential time points and provide and examine
the effects of both folic acid dose and MTHFR genotype and the
interaction between dose and genotype. So that the results could
be generalized to the population from which the study participants
were selected, the model was weighted to account for sampling.
The percent DNA methylation and enrollment RBC folate
concentrations were log-transformed to normalize the data for
modeling purposes only. The models used folic acid dose, MTHFR
genotype, age, body mass index (BMI), and enrollment RBC folate
concentration as covariates. In coagulated samples, the folic acid
intervention and withdrawal were modeled separately to allow for
the differential effects of covariates on the different exposures as
specified.
Logistic regression was used to determine factors associated with
a $25% decrease or a $50% decrease in DNA methylation after
withdrawal of folic acid supplementation in coagulated samples.
The models included folic acid dose (using the 4,000-mg/day dose
as referent), MTHFR genotype (TT genotype as referent), age, and
baseline RBC folate concentration. SAS-JMP Genomic and SPSS
statistical packages were used to analyze the data.
Power analysis based on the SD at enrollment in coagulated
samples indicated that there was .80% power to detect
differences of $5% with five samples. Given the larger SD after
the intervention in coagulated samples, power analysis indicated
.90% power to detect differences of .15% using 12 (the smallest
coagulated subgroup sample size) samples per group.
Results
Demographic, vitamin B12, and hemoglobin data at
baseline in the subsample used for DNA methylation
analysis
The mean age of the women was 30.464 years and did not differ
between treatment groups (Table 1). There were no differences in
the average BMI, plasma vitamin B12, or hemoglobin concentra-
tions for participants in the three folic acid supplementation groups
(Table 1).
Blood folate and homocysteine concentrations in the
subsample used for DNA methylation analysis
Detailed analysis of the plasma and RBC folate and homocys-
teine response and response by MTHFR genotype are published
elsewhere [7,8]. The effects of folic acid supplementation and
withdrawal on folate and homocysteine concentrations for the
stratified random sample use in this study are presented in Table 1.
Blood folate concentrations increased after initiation of folic acid
supplementation in each group (trend 4,000 mg.400 mg.100 mg)
with a sharp decrease after 3 months of folic acid withdrawal.
Folic Acid and Changes in DNA Methylation
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associated with initiation of folic acid supplementation—
coagulated blood
Significant changes in DNA methylation (determined by LC-
MS/MS expressed as the percentage of 5-methyl-deoxycytidine
[%MdCyt] in total genomic deoxycytidine [MdCty plus unmethy-
lated dCyt]) were observed with initiation of folic acid supplemen-
tation for all three dose groups and MTHFR genotypes (Fig. 2). At
enrollment, there was minimal intra-individual variation in global
DNA methylation (unadjusted average %MdCyt=4.42 [SD+/
20.12], min. 4.12, max. 4.74), comparable to previous estimates of
DNA methylation levels in a variety of mammalian tissues [12,24].
There was a decrease in DNA methylation in all participants after 1
month. After 1, 3, and 6 months, there was increased intra-
individual variation in global DNA methylation (after 1 months
unadjusted mean: %MdCyt=3.83 [SD+/20.42], min. 1.06, max.
4.33; after 3 months unadjusted mean: %MdCyt=3.83 [SD+/
20.40] min. 1.12, max. 4.55; after 6 months of supplementation
unadjusted mean: %MdCyt=4.03 [SD+/20.72], min. 0.65, max.
5.25). At the end of 6 months, 27% of individuals with a MTHFR T
allele showed a $5% increase in methylation (max+19.5%);
however, no increases were observed for individuals with the
MTHFR CC genotype. In general, variability in DNA methylation
levels increased with increasing folic acid dosage, time and presence
of the MTHFR C allele.
In response to 1 month of folic acid supplementation, an overall
14% decrease (P,0.0001) was observed in global DNA methyl-
ation when using a general linear model for repeated measures
(GLMRM) adjusted for both potential confounders and weighted
to allow for inference to the population (Fig. 2 and supplemental
Table S1). The models showed that the decrease in DNA
methylation at 1 month was independent of folic acid dose
(P.0.5) and MTHFR genotype (P.0.3).
When stratified by folic acid dose and genotype, a similar pattern
of DNA methylation decrease after initial of supplementation was
observed throughout the course of the intervention (Fig. 2). An
interaction between dose and genotype with DNA methylation
(P,0.001) was found. The estimated means of the methylation level
at 6 months in the 100 mg/day MTHFR TT genotype group and in
the 4,000 mg/day MTHFR CT group were not significantly
different from the estimated mean at enrollment (Fig. 2).
Global DNA methylation changes associated with the
withdrawal of folic acid supplementation—coagulated
blood
The change in DNA methylation level observed between
enrollment and 3 months after the withdrawal of folic acid
supplementation varied from a 94% decrease to a 17% increase
(unadjusted mean %MdCyt 3.46 [SD+/21.17], min. 0.24, max.
4.9). A partial-replicate study employing identical independent
procedures yielded essentially identical results (data not shown).
An additional overall 23% decrease (P,0.001) in percent global
DNA methylation was observed in response to folic acid
withdrawal after supplementation using an overall weighted,
adjusted general linear model for repeated measures (Fig. 2 and
supplemental Table S1). Differences in magnitude of the decrease
Table 1. Participant characteristics and response to folic acid supplementation and termination of supplementation.
Folic acid dosage
100 mg/d 400 mg/d 4,000 mg/d
Mean SD Mean SD Mean SD
Age 30.6 4.1 30.7 3.7 29.9 4.4
Body mass index 23.5 3.9 24.1 4.9 24.2 4.3
B12 (pmol/l) screening 287.2 122.4 277.0 96.9 287.2 99.2
Plasma folate (nmol/L) screening 10.5 5.2 10.0 4.9 9.9 4.4
1 month 19.5 8.1 31.4 12.2 103.0 129.3
3 months 23.4 12.1 39.2 16.3 92.2 122.8
6 months 36.7 70.1 40.9 19.8 56.3 34.3
3 months withdrawal (9 mo) 16.2 5.5 17.4 6.3 19.2 5.8
Red blood cell folate (nmol/L) screening 685.2 292.8 669.7 365.6 685.1 309.7
1 month 706.2 360.9 785.2 292.5 1031.0 470.9
3 months 712.5 245.6 916.6 289.1 1543.8 707.0
6 months 821.9 363.8 1147.8 546.3 1608.7 835.1
3 months withdrawal (9 mo) 653.2 259.1 726.0 298.3 821.4 337.8
Plasma homocysteine (Hcy)(mmol/L) screening 8.2 4.4 8.9 6.5 8.9 5.4
1 month 8.9 4.6 8.7 6.0 7.7 3.3
3 months 7.0 3.6 6.5 4.2 6.2 3.0
6 months 6.8 2.7 7.1 5.6 7.4 4.5
3 months withdrawal 8.1 4.0 8.0 5.2 7.7 4.1
Hemoglobin (Hgb) (g/L) screening 138.3 9.6 135.7 9.0 133.6 8.1
6 months 146.8 15.2 147.0 13.5 148.0 13.0
3 months withdrawal (9 mo) 136.4 10.9 136.9 10.9 136.0 10.6
doi:10.1371/journal.pone.0028144.t001
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dose (Fig. 2). There was a clear dose response by MTHFR
genotype, with the greatest decrease in DNA methylation observed
among the MTHFR CC (41.7%), CT (20.1%), and TT (3.6%-non
significant decrease). The genotype-dose combinations with the
largest decrease in % methylation were among individuals with the
MTHFR CC genotype receiving 100 mg/day (57.7%) , with a
small, non-significant mean increase in DNA methylation among
the 400 mg/day MTHFR TT group (6.6%). The 100 mg/day
group showed a clear dose-response, with the largest drop
observed for the CC genotype group (57.7%), followed by the
CT (25.9%) and TT (1.2%) groups compared to the %
Figure 2. Global DNA methylation changes in response to folic acid supplementation and withdrawal among women of
reproductive age- Coagulated Blood. Enrollment % DNA methylation (%MdCyt/total cytosine) is shown in green, DNA methylation level during
the supplementation trial is shown in blue and DNA methylation level after the discontinuation of supplementation (withdrawal) is shown in red. A.
Overall estimated mean %MdCyt and 95% Confidence Intervals (CI) were generated from a general linear model of repeated measure model
(GLMRM) containing; folic acid dose, MTHFR genotype, age, BMI, enrollment RBC and time (0,1,3,6,9 months data) weighted to adjust for sampling.
The model showed a significant interaction of folic acid dose and MTHFR genotype (P,0.001). B. Estimated mean %MdCyt and 95% CI were
generated from a GLMRM stratified by folic acid dose; adjusting for MTHFR genotype age, BMI, enrollment RBC and time and weighted to adjust for
sampling. C. Estimated mean %MdCyt and 95% CI were generated from a GLMRM stratified by MTHFR genotype; adjusting for folic acid dose, age,
BMI, enrollment RBC and time and weighted to adjust for sampling. D. Estimated mean %MdCyt and 95% CI were generated from a GLMRM stratified
by MTHFR genotype and folic acid dose; adjusting for age, BMI, enrollment RBC and time and weighted to adjust for sampling. * Significant difference
compared to enrollment p,0.01
– T Significant difference between the DNA methylation level at the end of the supplementation trial (6 months) and
after the discontinuation of supplementation (9 months) p,0.01.
doi:10.1371/journal.pone.0028144.g002
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receiving higher doses, the CT genotype more closely resembled
the CC genotype in the 400 mg/day and the TT 4000 mg/day
groups. The model revealed an interaction of dose and genotype
(P,0.001) for the withdrawal phase of the trial.
Following folic acid withdrawal, there was a strong association
between a decrease in DNA methylation of $25% (vs. ,25%) and
genotype: MTHFR CC vs. TT (adjusted odds ratio [aOR] 12.9,
95% CI 6.4, 26.0) and CT vs. TT (OR 2.8, 95% CI 1.6, 5.1), as
seen in a logistic regression model adjusted for age, baseline RBC,
and folic acid dosage. Similar trends were seen if a decrease of
$50% in DNA methylation (vs. ,50%) was used in the model,
with associations noted with genotype (MTHFR CC vs. TT [aOR
20.1, 95% CI 7.8, 51.3) and CT vs. TT [aOR 2.0, 95% CI 0.8,
5.2]).
[
3H] Methyl-acceptance assay—Coagulated blood
Pairs of samples (n=7) were also analyzed by the [
3H] methyl-
acceptance assay to confirm the LC-MS/MS, data: 4 pairs with
large decreases between enrollment and withdrawal ranging from
289% to 279% by LC MS/MS and 3 pairs with moderate
changes (24% to+ 0.9%). The results indicated that samples with
moderate changes in DNA methylation by LC-MS/MS (mean
21%, SD 2.2) also showed moderate changes when analyzed
using the methyl-acceptance assay (mean 4%, SD 24), while those
with large decreases in percent DNA methylation by the LC-MS/
MS (mean=286%, SD 5) assay, were also found to have large
increases in methyl-acceptance (mean=94%; SD 3) (indicating
large decreases in methylation).
Determination of global DNA methylation changes
associated with initiation of folic acid supplementation
and withdrawal of supplementation_Uncoagulated
blood
In uncoagulated samples, the %MdCyt was very similar to the
baseline levels in the DNA from coagulated blood samples
(%MdCyt=4.42 [SD+/20.12] coagulated samples vs. mean
%MdCyt=4.46 [SD+/20.15] uncoagulated samples). At baseline
there were no significant difference between the three MTHFR
genotypes (ANOVA, P.0.9 for all comparisons, mean
%MdCyt=4.46 [SD+/20.15]). There was no increase in the
variation in methylation level between the intervention groups at 9
months %MdCyt=4.46 [SD+/20.15]. Using a general linear
model for repeated measures, there were no changes in mean
methylation levels in response to folic acid supplementation or the
termination of supplementation in the 400 mg/day and 4,000 mg/
day group doses or within the 400 mg/day and 4,000 group mg/
day doses among the three MTHFR genotypes (Fig. 3 and
supplemental Table S2).
Comparison of DNA methylation levels side by side in
samples extracted from uncoagulated blood and
coagulated blood
We found high correlation between analytical runs .2 years
apart for the DNA samples re-extracted and assayed from clots
(n=20: baseline clots 1st run %MdCyt=4.39 [SD+/20.11];
baseline clots 2nd run %MdCyt=4.21 [SD+/20.13]; 1 month
clot 1st run %MdCyt=3.96 [SD+/20.17] ; 1 month clots 2nd
run %MdCyt=3.85 [SD+/20.23]).
To examine samples with the most consistent (1 month) and
largest decreases (9 month MTHFR CC), we assayed samples
(n=17 participants) from the 100 mg/day at the 1 and 9 month
time points, both in DNA extracted from blood and in DNA
extracted from clots not previously assayed (blinded and extracted
using the same protocol after the initial processing required for
homogenization of the clot). We found that, at 1 month, DNA
extracted from clots %MdCyt=3.82 [SD+/20.38] and in
uncoagulated samples was %MdCyt=4.24 [SD+/20.22], and
at 9 months in DNA extracted from clots was %MdCyt=3.04
[SD+/21.50] and in DNA extracted from uncoagulated blood
was %MdCyt=4.3 [SD+/20.15], confirming the differences
between the sample types and the consistency of results across
samples and time.
Discussion
This is the first population-based randomized intervention study
to describe the global DNA methylation response to the initiation
of and withdrawal from folic acid supplementation. In this study,
no global methylation changes were associated with up to
4,000 mg/day folic acid supplementation for 6 months; when the
analysis was completed using DNA extracted from uncoagulated
blood. However, significant changes in DNA methylation were
found in response to supplementation with folic acid and the
withdrawal of supplementation in DNA extracted from coagulated
blood that were time-, dose-, and genotype-dependent, suggesting
that folic acid intake might impact a coagulation-mediated
process.
Previous small-scale feeding studies have provided evidence that
global DNA methylation decreases in response to moderate folate
intake/depletion [13,14] and increases upon subsequent repletion
[14], thus an initial increase in DNA methylation was anticipated
in the current study. However, no changes in DNA methylation
levels were found in uncoagulated samples, which might reflect
more closely circulating blood and the samples used in previous
studies. One possible explanation for the lack of change observed
in this study was that DNA methylation was already optimal
among our participants, and would not have been expected to
increase with folic acid supplementation. Alternatively, the
differential results between studies possibly could be explained
by the fact that previous analytical methodology used to estimate
DNA methylation lacked the accuracy and precision of the LC-
MS/MS method to measure the true level of genome-wide
methylation [12].
Surprisingly, the data from this study also suggested that folic
acid supplementation led to changes in DNA methylation levels in
blood cells that were allowed to coagulate and that these changes
were time-, dose-, and MTHFR genotype-dependent. The
differential results by blood sample type were unexpected and
have not been reported previously. To rule out methodological
error, we replicated the quantitation of DNA methylation from
blood clots by LC MS/MS up to four times, including reblinding
and side-by-side analysis from extraction through analysis, with
high reproducibility of results between analytical runs. We also
estimated DNA methylation in the coagulated samples by using a
completely different methodology (
3H methyl acceptance), which
confirmed the pattern and magnitude of change in the coagulated
samples. Moreover, the analogous change in DNA methylation
observed between the two assays, the decrease in %MdCty (LC-
MS/MS), and the increase in unmethylated dCyt ([
3H] methyl
acceptance assay), could not be explained by changes in the quality
of the DNA used in the assay. The [
3H] methyl acceptance assay
requires that the DNA be high quality and double stranded; thus,
low-quality DNA would result in a decrease in [
3H] methyl
acceptance capacity (not an increase, as was observed in this
study). In contrast, the LC-MS/MS assay is independent of DNA
quality, as the DNA is digested to nucleosides as part of the assay.
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28144Figure 3. Global DNA methylation changes in response to folic acid supplementation and withdrawal among women of
reproductive age- Uncoagulated Blood. Enrollment % DNA methylation (%MdCyt/total cytosine) is shown in green, DNA methylation level
during the supplementation trial is shown in blue and DNA methylation level after the discontinuation of supplementation (withdrawal) is shown in
red. A. Overall estimated mean %MdCyt and 95% Confidence Intervals (CI) were generated from a general linear model of repeated measure model
(GLMRM) containing; folic acid dose, MTHFR genotype, age, BMI, enrollment RBC and time (0,1,3,6,9 months data) weighted to adjust for sampling.
GLMRM modeling shows no significant effect of the MTHFR genotype or folic acid dose or an interaction of dose and genotype (all P.0.8). B.
Estimated mean %MdCyt and 95% CI were generated from a GLMRM stratified by folic acid dose; adjusting for MTHFR genotype age, BMI, enrollment
RBC and time and weighted to adjust for sampling. C. Estimated mean %MdCyt and 95% CI were generated from a GLMRM stratified by MTHFR
genotype; adjusting for folic acid dose, age, BMI, enrollment RBC and time and weighted to adjust for sampling. D. Estimated mean %MdCyt and 95%
CI were generated from a GLMRM stratified by MTHFR genotype and folic acid dose; adjusting for age, BMI, enrollment RBC and time and weighted to
Folic Acid and Changes in DNA Methylation
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28144Therefore, these data supported the conclusion that the discrep-
ancy in DNA methylation levels between blood sample types could
not be attributed to methodological error.
The differential results from coagulated and uncoagulated blood
were present only in association with folic acid supplement use and
the large decreases in DNA methylation observed in coagulated
blood after supplement withdrawal were associated strongly with
the MTHFR genotype and consistently replicated and confirmed
across time using different analytical methodology. The fact that
the level of DNA methylation was the same in both sample types at
baseline, with differences observed only after the initiation of folic
acid supplementation, confirms the influence of folic acid
supplementation and MTHFR genotype in DNA exposed to the
clotting process. Therefore, the time-, dose-, and MTHFR
genotype-dependent changes in DNA methylation levels in the
coagulated DNA samples in response to folic acid supplementation
and withdrawal cannot be considered an artifact. These data raise
a series of questions related to the possible influence of coagulation
and the MTHFR 677CRT genotype on DNA methylation when
folic acid exposure is altered and sets a research agenda for these
intriguing new questions to be investigated.
Why do global methylation levels differ between
coagulated and uncoagulated blood samples?
Differential Cell Type Distribution. In this study we
utilized uncoagulated (EDTA) blood (spun down with the plasma
removed) as one source of DNA. The buffy coat (the cell fraction
most often used in genetic studies) should be contained completely
in this fraction. Ideally, the uncoagulated and the coagulated
samples (obtained through simply allowing a clot to form, then
spinning down and removing the sera) should contain similar
amounts and types of the nucleated blood cells (all of them), which
would contribute to the DNA assayed for methylation status;
however; in practice, this might not be the case. In our study, it is
possible that some of the observed changes in DNA methylation in
response to supplementation might have been due to differences in
leukocyte cell types or specific cell subtype responses from which
DNA was extracted, given that whole blood contains a mixture of
cells with different turnover rates (e.g., neutrophils, lymphocytes,
and monocytes) [25] whose DNA methylation patterns might differ
[26]. The fractionation procedures could have left different
populations of cells in the aqueous fraction (plasma or sera,
respectively). To address this issue in the available samples, we
compared the DNA yields from coagulated and uncoagulated blood
and correlated DNA yield in the clots with methylation level.
Samples yielded the expected amount of DNA based on the blood
volume of the initial blood draw. There was variation in DNA yield,
whichistobeexpected whenusingclots[27];however;therewasno
correlation between DNA yield and global methylation levels in the
samples. It seems unlikely that different cell types in the clots would
havebeena drivingmechanismforthe observed reductions in DNA
methylation for a number of reasons. First, to achieve even a 14%
decrease in methylation (as observed with supplementation), an
extensive shift in cell type distribution within the leukocyte cell
populationwould have been required (thisis possible,butnot likely).
Second, achievement of a large genotype-dependent reduction (up
to 90%) without a concomitant drop in DNA yield seems
improbable. Additionally, many different human tissue types (e.g.,
heart, liver, lung, spleen, lymphocyte, brain, and thymus) among
humansappearto exhibitlittlevariation inglobalDNAmethylation
(mean=4.52%; range=4.28%–4.85%) [28] in contrast to ,14%
promoter of CpG sites have been reported to vary between tissues
[29]. Moreover, the level of DNA methylation in monocytes from a
U.S. study (4.45+/20.12%; unpublished data) was similar to that
observed for whole blood DNA at enrollment in this study in the
clotted DNA samples (4.42+/20.12%). The fact that no differences
were detected in DNA methylation at baseline between the
coagulated and uncoagulated samples argues against there being
differences in the cell population between the two sample types.
Other processes associated with de-/hypo-
methylation. Apoptosis is the primary consideration in any
discussion of de-/hypomethylation because of the clear connection
between hypomethylation and apoptosis [30,31]. This study was
not designed to assess if the samples allowed to coagulate were
undergoing apoptosis. A limited number of samples run on
agarose gels did not show a definitive apoptotic banding pattern or
degradation that was limited to samples with decreases in assayed
DNA methylation level (data not shown). However, since this
study was not designed to directly assay for evidence of apoptosis,
a potential influence of this process cannot be ruled out and
warrants further study.
Generally, decreases in global methylation are thought to be a
result of a reduced availability of substrate during DNA
replication. However, it is unlikely that the hypomethylation seen
in our study is replication-dependent because of the limited
window of time (1–2 hours) and the large decreases reported.
Active demethylation has been observed embryonically; there is a
wave of demethylation as DNA methylation patterns are reset in
the early embryo [32]; however, the identity the demethylase
remains unknown [33]. It is possible that the hypomethylation
observed in our study may be the result of active demethylation, as
part or consequence of the 2 hours allowed for coagulation.
The study of coagulation has centered largely on factors in the
plasma that induce coagulation. Elevated homocysteine concen-
tration consistently has been shown to be associated with venous
thrombosis; however, the nature of the association remains an
active area of investigation [6,34]. Among populations with higher
folate/folic acid intake, such as those in North America and
Europe, there has been no consistent association between
thrombosis and MTHFR genotype [6,34]. However, among
populations in Asia and Latin America, the MTHFR T allele has
been shown to be associated more consistently with an increased
risk of venous thrombosis [6,35]. It is interesting to consider the
fact that the largest decreases in DNA methylation in our present
study were following withdrawal of supplementation in those with
the MTHFR C allele, which might be more resistant to
coagulation. In our previous study, elevated homocysteine was
associated strongly with the MTHFR T genotype among this
population [8]. Work in human cell lines suggests that hypo-
methylation is a mechanism of hyperhomocysteinemia-induced
cell damage [36]. Intriguingly, a small plasma proteomics study of
folic acid supplementation (1.2 mg for12 weeks) found that folic
acid supplementation was associated with changes in proteins
involved in increased coagulation [37]. Additionally, taking a folic
acid supplement during pregnancy has been shown to be
associated with a reduction in hypercoagulability [38]. There is
a balance between coagulation and hemorrhage, and MTHFR
adjust for sampling. All pairwise comparisons between enrollment and months of supplementation and withdrawal were non-significant and showed
a ,+/2 3% change which is within the variability of the LC-MS/MS assay. All subjects included in this table are a subset of coagulated results in
Figure 2.
doi:10.1371/journal.pone.0028144.g003
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equilibrium. Future research will be needed to determine any
effects on coagulation of folic acid supplementation and the
termination of supplementation.
Future research
Additional basic science research is needed to replicate our
findings and provide insight into additional biological mechanisms
that might explain our results. The differential results between
sample types were not present at baseline, becoming evident only
after initiation of the folic acid supplementation trial. Currently,
studies are underway to determine if there are differences in the
coagulated and uncoagulated samples of individuals who were
B12-deficient and anemic who were enrolled in the study, but not
eligible to participate in the intervention trial. The results from this
study will help to determine if this phenomenon is limited to folic
acid exposure or might be a broader effect of micronutrient status.
Although we have shown that in the uncoagulated blood there
are no global methylation changes, this does not rule out changes in
specific genes or genetic loci. Tests currently are under way in
uncoagulated samples to determine if changes in specific genes in
response to folic acid supplementation or the termination of
supplementation, or both, can be detected. Additionally, controlled
studies are needed to determine if these results can be replicated
among populations both exposed and unexposed to folic acid, as
well as other racial and ethnic and nutritional status groups.
Implications
Although the present study does not provide definitive
explanations regarding the observed influence of blood clotting,
folic acid supplementation, and the MTHFR genotype on DNA
methylation, the findings do inform future studies of DNA
methylation. Specifically, these results provide new opportunities
for basic researchers to identify pathways of DNA demethylation
that occur during coagulation that are sensitive to MTHFR
genotype and folic acid exposure. These data have implications for
the design of future studies since clotted samples often are
available as a source of genomic DNA for DNA methylation
analyses in human metabolic and population surveys. DNA
methylation analysis currently requires genomic DNA in relatively
high quantities (several hundred ng) which can be problematic for
large studies involving human participants using archival samples.
The clots from serum collection are an often available and
unutilized source of DNA; however, our study strongly suggested
that this sample type does not show the same results as those
obtained from uncoagulated blood (which might represent more
closely what is present in circulating blood). The study highlights
the importance of sample selection for those planning epigenetic
studies. Additionally, these data provide the impetus for further
investigations to clarify the observed differences in DNA
methylation between coagulated and uncoagulated blood that
are suggestive of an effect of folic acid on a coagulation-mediated
process.
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